Today: 30 April 2026
Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE
12 January 2026
1 min read

Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

New York, Jan 12, 2026, 15:40 ET — Regular session

Shares of Dave Inc (DAVE.O) dropped 8.8% to $218.29 in late-afternoon trading Monday, after earlier fluctuating between $212.10 and $247.74. The fintech’s stock had closed Friday at $239.35, with roughly 1.1 million shares changing hands by mid-afternoon, according to market data.

The drop came as investors backed away from credit-sensitive stocks following U.S. President Donald Trump’s call for a one-year cap on credit card interest rates at 10%, starting Jan. 20. On the docket for Tuesday is the U.S. consumer price index (CPI), a crucial inflation measure that could shift expectations around Federal Reserve rate cuts. “We need to see some type of action before the market will actually react to it in a meaningful way,” said Jordan Rizzuto, chief investment officer at GammaRoad Capital Partners.

U.S. stocks were creeping up, the Nasdaq gaining roughly 0.5% and the S&P 500 reaching an intraday record, despite weakness in the financial sector. Peter Cardillo, chief market economist at Spartan Capital Securities in New York, noted the investigation headline involving Fed Chair Jerome Powell had been “telegraphed,” so the market shrugged it off.

Dave’s slump mirrored a wider slide in consumer-finance and fintech stocks. Upstart fell roughly 7.0%, Affirm dropped 6.7%, and SoFi declined 2.8%. LendingClub, however, saw minimal movement.

Dave positions itself as a neobank and fintech platform, offering products like ExtraCash — a 0% interest overdraft through a banking partner — and Dave Checking, a digital deposit account. In 2024, it reported roughly $347 million in revenue and net income near $58 million, according to LSEG data on the Reuters company page.

Monday’s moves can hit smaller consumer fintechs hard, as changes in rate expectations swiftly affect perceptions of funding costs and borrower strain. When sentiment turns sour on lenders, selling often goes too far.

Legal and regulatory clouds loom as well. In late 2024, the U.S. Justice Department lodged a complaint and launched a civil enforcement action against Dave and its CEO, Jason Wilk. They allege the company deceived users over cash advances and imposed hidden fees. Dave pushed back, calling many of the claims inaccurate and pledging a defense.

Another risk is that policy chatter hardens into actual rules. A rate cap designed for credit cards won’t necessarily apply to every consumer-finance product. Yet investors often sell off the entire sector upfront, then figure out the specifics afterward.

Investors now turn to Tuesday’s CPI data and the start of major U.S. bank earnings, with JPMorgan Chase leading off on Jan. 13. These updates could shift views on interest rates and consumer credit trends in the coming weeks.

Stock Market Today

  • Bristol Myers Squibb Beats Q1 Earnings and Revenue Estimates, Shares Rise
    April 30, 2026, 9:56 AM EDT. Bristol Myers Squibb (BMY) reported adjusted quarterly earnings of $1.58 per share, surpassing the Zacks Consensus Estimate of $1.44, marking a 9.67% earnings surprise and continuing its streak of positive surprises over the past year. Revenues reached $11.49 billion, 5.25% above estimates and growing slightly from $11.2 billion a year ago. Shares have climbed 6.8% year-to-date, outperforming the S&P 500's 4.2% gain. Despite mixed recent earnings estimate revisions, BMY holds a Zacks Rank #3 (Hold), suggesting near-term performance in line with the market. The consensus for the next quarter expects EPS of $1.64 on $11.78 billion revenue, with $6.27 EPS on $47.03 billion revenue forecasted for the fiscal year. Industry trends in Medical - Biomedical and Genetics also play a significant role in stock outlook.

Latest article

Zoom Sets Earnings Date as AI Growth and Margins Move Back Into Focus

Zoom Sets Earnings Date as AI Growth and Margins Move Back Into Focus

30 April 2026
Zoom will report first-quarter fiscal 2027 earnings on May 21 after the market closes. The stock rose 5.07% Wednesday to $95.76, just below its 52-week high, after a Vanguard unit disclosed a 5.05% passive stake. Last quarter, revenue climbed 5.3% to $1.247 billion. Investors await updates on AI strategy and enterprise growth.
FuelCell Energy Stock Jumps as AI Power Boom Puts FCEL Back in Play

FuelCell Energy Stock Jumps as AI Power Boom Puts FCEL Back in Play

30 April 2026
FuelCell Energy shares jumped 37% Wednesday, trading near a one-year high at $13.64 premarket Thursday, as investors bet on fuel-cell demand for AI data centers. Rival Bloom Energy reported Q1 revenue up 130% to $751.1 million and will supply up to 2.45 GW of fuel cells to Oracle’s Project Jupiter. FuelCell’s January-quarter revenue rose 61% to $30.5 million but it posted a net loss of $26.1 million.
America’s Credit Split Is Getting Worse: TransUnion Data Shows Who Is Being Squeezed

America’s Credit Split Is Getting Worse: TransUnion Data Shows Who Is Being Squeezed

30 April 2026
TransUnion reported a sharper split in U.S. consumer credit, with 15 million more borrowers in the super-prime tier since 2019, while near-prime and subprime borrowers face rising debt-to-income ratios. Bankcard balances hit $1.12 trillion in Q1, and personal loan originations reached 7.6 million in Q4, both up from a year earlier. Mortgage delinquencies of 60 days or more rose to 1.57%.
HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test
Previous Story

HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

Nvidia stock barely moves after hours as $1 billion Eli Lilly AI lab plan lands
Next Story

Nvidia stock barely moves after hours as $1 billion Eli Lilly AI lab plan lands

Go toTop